Dapagliflozin reduces albuminuria on top of RAS blockade in type 2 diabetic patients with moderate renal impairment

By /

This Presentation was given by Davide Sjostrom, from AstraZeneca, M?lndal, Sweden. It was presented at the World Congress of Nephrology 2015 in Cape Town during Session 7: Diabetic nephropathy: New insights from the bench to the bedside

 

Additional Info

  • Language:
    English
  • Contains Audio:
    Yes
  • Content Type:
    Presentations
  • Source:
    ISN
  • Event:
    WCN 2015
  • Year:
    2015
  • Members Only:
    No



Read 377 times

Scroll to Top